ORIC PHARMACEUTICALS INC. - COMMON STOCK

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

15 4 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 4 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

04 4 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

11 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

06 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

05 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

14 2 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 2 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

31 1 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

22 1 2024 08:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

08 1 2024 08:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 1 2024 16:30:00 提供 Nasdaq GlobeNewswire

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

11 12 2023 12:00:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 12 2023 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

09 11 2023 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

06 11 2023 16:10:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 11 2023 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

02 11 2023 09:00:00 提供 Nasdaq GlobeNewswire